CClinicalTrials.gg
CompletedNCT05090956(MISAP)Updated Jul 20, 2026

Developpement of 3T MRI Protocol

An interventional study of mri in Healthy, Adult ALL and MRI, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Since January 2010, a new magnetic resonance imaging scanner (Philips 3T, Achieva) is installed on the Baudot Building in Toulouse hospital. This tool, is completely dedicated to the research. It was installed with sequences RMN supplied by the manufacturer.

Imagers also contain an instrumentation susceptible to evolution and/or to adjustment (antennas radio frequency, sheath of gradients, elements of physiological monitoring (for example control of the breath), regulation of the homogeneity of the magnetic field).

This MRI scanner and this instrumentation are used for anatomical examinations or for paradigms of cognitiveresearch (for example of detection of intellectual activations following simple stimuli of fingers movement, visual tasks, or of mental processes).

The developpement of this equipment is going to favor the emergence of numerous projects and new themes, up to there adressed by other techniques (psychophysics, EEG).

To obtain good quality signals and know the practical limits of this imager, it is thus necessary that the researchers doctors, physicists and engineers, can finalize on volunteers' significant number, all the sequences RMN necessary for the use of these tools for the research.

These developments are going to get organized around four main axes:

1 the control of the geometrical distortions (generated by the introduction of an object within the magnetic field) 2 Optimization of the parameters of sequences to improve the contrast and the spatial resolution of the obtained images 3 the development of new sequences 4 the feasibility study of the protocols of functional MRI

02

Conditions studied

  • Healthy
  • Adult ALL
  • MRI
03

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,061 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 490 are open to participants now.

This study's enrollment of 230 is above the median of 40 across 1,653 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Healthy adult, age = 18 years;

  • Visual, hearing , oral or written capacities and expression sufficient for the suitable realization of the tests;
  • Obtaining of the informed consent of the subject.

Exclusion criteria

Exclusion Criteria:

  • Subjects presenting a neurological, psychiatric history;
  • Subjects under chronic medication which can influence the intellectual activity;
  • Subjects presenting a contraindication to the MRI (carriers of a pacemaker, an implanted material(equipment) activated by an electric, magnetic or mechanical system, carriers of haemostatic clips of anévrysmes intracérébraux or carotid arteries, carriers of orthopaedic, claustrophobic implants);
  • Subjects refusing to be informed about the possible presence of an anatomical anormality;
  • administrative Problems: impossibility to give about the information, no insurance, refusal to sign the consent, under guardianship subject ;
  • Subjects participating in another protocol • pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    control

    MRI exam; The sequences to be performed will be presented to the subject according to the focus to be performed. maximal duration of the exam: 2 hours (including subject set up)

    Other: mri

Interventions

  • Othermri
06

What researchers measure

Primary outcomes

  1. Assessment of distortion of MRI images

    Time frame: 90 months

  2. Measurement of contrasts of MRI sequence

    By using available software such as MRICro, Image J, Matlab or other post-processing tools developed as required

    Time frame: 90 months

  3. Measurement of MRI sequence resolution

    To estimate the resolution by measuring the signal-to-noise ratio using standard software such as MRICro, Image J, Matlab or other post-processing tools developed as required

    Time frame: 90 months

07

Study locations

1 site
  • Inserm U825
    Toulouse, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05090956
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Jun 8, 2012
Primary completion
Jan 2020
Completion
Jan 29, 2020
Last update
Jul 20, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion